Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01837238 · ClinicalTrials.gov registry record · NA
Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients
A NA study, sponsored by University of Illinois at Urbana-Champaign.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT01837238 is a NA study that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 41 participants.
The verdict
NCT01837238, a NA study, has completed, sponsored by University of Illinois at Urbana-Champaign.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of 6 months of daily beta-hydroxy beta-methylbutyrate (HMB) supplementation on the physical function and the health of bones, arteries and heart in hemodialysis patients.
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT HMB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01837238
The ClinicalTrials.gov registry entry for NCT01837238 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Urbana-Champaign, which has 129 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01837238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01837238 about?
NCT01837238 is a clinical study titled "Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients". The purpose of this study is to examine the effect of 6 months of daily beta-hydroxy beta-methylbutyrate (HMB) supplementation on the physical function and the health of bones, arteries and heart in hemodialysis patients.
What is the current status of trial NCT01837238?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2012-11. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01837238?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), HMB (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01837238?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.